Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Indian Healthcare...

    Indian Healthcare sector may touch Rs 8.6 Trillion by FY22: Report

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 14 May 2018 8:40 AM  |  Updated On 14 May 2018 8:40 AM
    Indian Healthcare sector may touch Rs 8.6 Trillion by FY22: Report

    The healthcare industry is expected to grow annually at 16-17 percent to reach to Rs 8.6 trillion by FY22 on the back of the Centre's Ayushman Bharat scheme which if implemented successfully can go a long way in meeting the severe shortage of healthcare infrastructure, says a brokerage report.


    The significant interest seen in acquiring Fortis Healthcare from multiple players both domestic as well as international ones including non-healthcare companies clearly signifies the attractiveness of the domestic healthcare industry, says the report.

    "We believe the key reasons for this interest are the shortage of healthcare infrastructure in the country, including bed capacity, medical practitioners etc, and government's mega plan of expanding healthcare reach across the country through Ayushman Bharat scheme," ICICI Securities said in a weekend note.

    Hospitals are expected to grow at 16-17 percent CAGR to reach to Rs 8.6 trillion by FY22 from Rs 4 trillion in FY17. That means if the above scheme is implemented successfully, healthcare delivery market can grow multi-fold, the report added.

    Interestingly, the present strength of doctors in the country can handle about double the current beds considering the ratio of beds per doctors in other emerging nations and also global average.

    "We believe the Ayushman Bharat scheme can provide significant growth opportunity for hospitals with a potential addressable market of Rs 50 trillion, though the successful implementation of the scheme has to be seen," it noted.

    Looking at the infrastructure shortage in the sector as a growth opportunity, the report notes that the country has just 0.7 beds per 1,000 people compared to the global average of 2.7 and the WHO recommendation of 3.5 beds. This is the key reason for hospitals to be in continuous expansion mode.

    In terms of manpower, the country has just 0.7 physicians and 1.7 nurses per 1,000 people compared to the global average of 1.4 physicians and 2.9 nurses respectively. Therefore, there is significant untapped opportunities.

    The ambitious Ayushman Bharat targets to provide healthcare coverage of Rs 5 lakh each for 100 million families. If implemented successfully, the scheme will be one of the largest government-funded healthcare schemes globally with an addressable market opportunity of Rs 50 trillion.

    Implementation of such a large plan will be challenging and time-consuming but if successful it can provide huge growth potential for the healthcare companies, the report said.

    The industry also has been facing several challenges lately on pricing and margins front. Considering the government focus on providing low-cost healthcare services to the poor, these challenges are expected to continue.

    However, despite these challenges, we believe the opportunity is significant for the industry to grow. To overcome such pricing challenges, hospitals should focus on diversified speciality mix rather than single therapeutic area, as diversification can lower the impact of such risks, says the report.
    Ayushman Bharat schemeCAGRdiversificationFortis Healthcarehealth newsHealthcareICICIimplementationIndiaIndian Healthcaremedical newsmedical news indiapotentialsectorsizetherapeuticWHO
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok